Engineered Small Extracellular Vesicles for Colon-Targeted Delivery: Design Review, Mechanisms, and Clinical Translation
This narrative review organizes sEV engineering strategies for colonic delivery but provides no human clinical efficacy data — the direction of effect remains insufficient for clinical recommendation.
| Population | Patients with colonic diseases (IBD, CRC, IBS, infectious colitis) — conceptual; no defined human cohort |
|---|---|
| Intervention | Engineered sEVs (cell-, plant-, or food-derived) for oral or parenteral colonic delivery |
| Comparator | Conventional colon-targeted delivery systems: liposomes, polymeric nanoparticles, metal nanoparticles |
| Outcome | Colonic delivery efficacy of sEVs; Inflammatory modulation in IBD (preclinical models); Tumor control in CRC (preclinical models); Safety and biocompatibility of sEVs; Batch reproducibility and production scale-up |
Summary of findings
| Outcome | Effect | 95% CI | Certainty | Clinical relevance | Notes |
|---|---|---|---|---|---|
| Colonic delivery efficacy of sEVs | No quantitative effect size reported; qualitative preclinical only | — | Very low | — | |
| Inflammatory modulation in IBD (preclinical models) | No pooled effect size; narrative synthesis only | — | Very low | — | |
| Tumor control in CRC (preclinical models) | No pooled effect size; narrative synthesis only | — | Very low | — | |
| Safety and biocompatibility of sEVs | Qualitative assessment only; in the clinical safety data aggregated | — | Very low | — | |
| Batch reproducibility and production scale-up | Identified as current limitation; in the quantitative benchmarks provided | — | Very low | — |
Context
Colonic diseases including IBD, CRC, IBS, and infectious colitis lack delivery systems that protect therapeutics during gastrointestinal transit and discriminate healthy from inflamed or malignant tissue. Small extracellular vesicles (sEVs) represent a biological platform with surface modification potential and microenvironment responsiveness. The review proposes a disease- and route-oriented decision framework, not a quantitative synthesis of clinical evidence.
What the study showed
The study is a narrative review without meta-analysis. It does not report aggregated efficacy data with 95% CI, RR, or NNT. It organizes preclinical and mechanistic evidence on how colonic microenvironment properties (pH, ROS, MMPs, microbial enzymes) can be exploited by engineered sEVs. The comparative platform table is qualitative, with no numerical effect values. No completed randomized clinical trial of sEVs for colonic diseases is reported.
How it was done
Narrative review (non-systematic) published in 2025/2026. No PROSPERO registration, no explicit PRISMA criteria, no standardized data extraction. Covers sEV biology, preparation methods, cargo loading, surface engineering strategies, and clinical translation perspectives for multiple colonic diseases.
Effect magnitude
No quantitative effect sizes with 95% CI are provided. The review does not aggregate numerical data from primary studies in a standardized manner.
Risk of bias
Narrative review without registered protocol; no formal risk-of-bias tool applied (AMSTAR-2 not used). Study selection is not systematized, with risk of publication and confirmation bias. Heterogeneity of sEV sources (human cells, plants, food) precludes generalization. No Phase II/III clinical data.
What this study does NOT prove
This study does not prove clinical efficacy of sEVs in any colonic disease in humans. It does not establish superiority over liposomes or polymeric nanoparticles on measurable clinical endpoints.
In clinical practice
No basis exists for clinical practice change based on this review. Clinicians should recognize sEVs as a preclinical and Phase I investigational platform. The qualitative comparison with liposomes and polymeric nanoparticles is useful for research platform selection, not clinical practice.
Limitations
Narrative review without registered protocol; no formal risk-of-bias tool applied (AMSTAR-2 not used). Study selection is not systematized, with risk of publication and confirmation bias. Heterogeneity of sEV sources (human cells, plants, food) precludes generalization. No Phase II/III clinical data.
What is still missing
Phase II/III randomized controlled trials of engineered sEVs in IBD and CRC, with standardized endpoints, are needed. Potency assays and batch reproducibility methods require validation before regulatory translation.
Technical appendix
Version history
- 1.0 · 2026-09-20 — Auto-generated under Evidence Standard v1.0